Cargando…

Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease

Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to th...

Descripción completa

Detalles Bibliográficos
Autor principal: TAKEUCHI, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Academy 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743860/
https://www.ncbi.nlm.nih.gov/pubmed/29021510
http://dx.doi.org/10.2183/pjab.93.038
_version_ 1783288640662667264
author TAKEUCHI, Tsutomu
author_facet TAKEUCHI, Tsutomu
author_sort TAKEUCHI, Tsutomu
collection PubMed
description Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model.
format Online
Article
Text
id pubmed-5743860
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japan Academy
record_format MEDLINE/PubMed
spelling pubmed-57438602018-01-04 Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease TAKEUCHI, Tsutomu Proc Jpn Acad Ser B Phys Biol Sci Review Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model. The Japan Academy 2017-10-11 /pmc/articles/PMC5743860/ /pubmed/29021510 http://dx.doi.org/10.2183/pjab.93.038 Text en © 2017 The Japan Academy This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
TAKEUCHI, Tsutomu
Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title_full Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title_fullStr Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title_full_unstemmed Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title_short Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
title_sort treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743860/
https://www.ncbi.nlm.nih.gov/pubmed/29021510
http://dx.doi.org/10.2183/pjab.93.038
work_keys_str_mv AT takeuchitsutomu treatmentofrheumatoidarthritiswithbiologicalagentsasatypicalandcommonimmunemediatedinflammatorydisease